{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T17:54:06Z","timestamp":1777139646963,"version":"3.51.4"},"reference-count":27,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2019,1,22]],"date-time":"2019-01-22T00:00:00Z","timestamp":1548115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Major New Drugs Innovation and Development","award":["2014ZX09201002-004"],"award-info":[{"award-number":["2014ZX09201002-004"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81703519"],"award-info":[{"award-number":["81703519"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Doctor Startup Science Foundation of Liaoning Province","award":["20170520257"],"award-info":[{"award-number":["20170520257"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>The aim of this study was to investigate the pharmacodynamics and pharmacokinetics of a new type of compound lansoprazole capsule in gastric ulcer rats and beagle dogs in order to confirm whether it is more effective in treating gastric ulcers and its rapid absorption. A rat model of gastric ulcers was used to evaluate the anti-ulcerogenic effect of the compound lansoprazole capsule. A fast and sensitive UPLC-MS\/MS method was developed to detect lansoprazole in dog plasma. Macroscopic and histological evaluation results revealed that the compound lansoprazole capsule is more effective in treating gastric ulcers as it was able to significantly reduce the gastric ulcer compared to the other groups. Additionally, it was able to enhance the expression of the antioxidant enzyme superoxide dismutase (SOD) and suppress lipid peroxidation as indicated by the reduction of malondialdehyde (MDA) and H+-K+-ATP activity. Furthermore, this capsule increased the expression of mucosal vascular endothelial growth factor (VEGF) and cyclic oxygenase 2 (COX-2). The established UPLC-MS\/MS method was successfully applied to the evaluation of pharmacokinetic parameters of lansoprazole in beagle dogs. The results indicate that the compound lansoprazole capsule had an advantage of rapid absorption. This study demonstrated that the compound lansoprazole capsule has better gastroprotective activity and that this might be related to its positive influence on oxidative stress and inflammation. This new type of compound lansoprazole capsule may be potentially useful in preclinical therapy.<\/jats:p>","DOI":"10.3390\/pharmaceutics11020049","type":"journal-article","created":{"date-parts":[[2019,1,24]],"date-time":"2019-01-24T03:52:32Z","timestamp":1548301952000},"page":"49","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Pharmacodynamics and Pharmacokinetics of a New Type of Compound Lansoprazole Capsule in Gastric Ulcer Rats and Beagle Dogs: Importance of Adjusting Oxidative Stress and Inflammation"],"prefix":"10.3390","volume":"11","author":[{"given":"Binbin","family":"Wei","sequence":"first","affiliation":[{"name":"School of Pharmacy, China Medical University, Shenyang 110021, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[{"name":"School of Pharmacy, China Medical University, Shenyang 110021, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huizhe","family":"Wu","sequence":"additional","affiliation":[{"name":"School of Pharmacy, China Medical University, Shenyang 110021, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingyan","family":"Liu","sequence":"additional","affiliation":[{"name":"School of Pharmacy, China Medical University, Shenyang 110021, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weifan","family":"Yao","sequence":"additional","affiliation":[{"name":"School of Pharmacy, China Medical University, Shenyang 110021, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minjie","family":"Wei","sequence":"additional","affiliation":[{"name":"School of Pharmacy, China Medical University, Shenyang 110021, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2019,1,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2165\/00003495-199244020-00007","article-title":"Lansoprazole. A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders","volume":"44","author":"Barradell","year":"1992","journal-title":"Drugs"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0939-6411(00)00152-1","article-title":"Bioequivalence evaluation of lansoprazole 30-mg capsules (Lanfast and Lanzor) in healthy volunteers","volume":"51","author":"Dugger","year":"2001","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1254\/fpj.131.149","article-title":"Pharmacological and clinical profile of lansoprazole (Takepron IV injection 30mg)","volume":"131","author":"Inatomi","year":"2008","journal-title":"Nihon YakurigakuZasshi"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1517\/14656566.2.10.1663","article-title":"Lansoprazole: Pharmacokinetics, pharmacodynamics and clinical uses","volume":"2","author":"Gremse","year":"2001","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1365-2125.1993.tb00386.x","article-title":"Age-related differences in the pharmacokinetics and pharmacodynamics of lansoprazole","volume":"36","author":"Hussein","year":"1993","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1111\/j.1572-0241.2003.08783.x","article-title":"Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: A five-way crossover study","volume":"98","author":"Miner","year":"2003","journal-title":"Am. J. Gastroenterol."},{"key":"ref_7","first-page":"158","article-title":"Meta-analysis of the efficacy of lansoprazole and omeprazole for the treatment of H. pylori-associated duodenal ulcer","volume":"7","author":"Zeng","year":"2015","journal-title":"Int. J. Physiol. Pathophysiol. Pharmacol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S1570-0232(02)00711-0","article-title":"Lansoprazole quantification in human plasma by liquid chromatography-electrospray tandem mass spectrometry","volume":"783","author":"Oliveira","year":"2003","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1248\/bpb.30.2238","article-title":"Population pharmacokinetics and proton pump inhibitory effects of intravenous lansoprazole in healthy Japanese males","volume":"30","author":"Sakurai","year":"2007","journal-title":"Biol. Pharm. Bull."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.jchromb.2004.11.052","article-title":"Determination of lansoprazole and two of its metabolites by liquid-liquid extraction and automated column-switching high-performance liquid chromatography: Application to measuring CYP2C19 activity","volume":"816","author":"Uno","year":"2005","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/j.jpba.2008.09.046","article-title":"Determination of lansoprazole in human plasma by rapid resolution liquid chromatography-electrospray tandem mass spectrometry: Application to a bioequivalence study on Chinese volunteers","volume":"48","author":"Wu","year":"2008","journal-title":"J. Pharm. Biomed. Anal."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.3109\/00498254.2012.687119","article-title":"Pharmacokinetics of lansoprazole and its main metabolites after single intravenous doses in healthy Chinese subjects","volume":"42","author":"Zhang","year":"2012","journal-title":"Xenobiotica Fate Foreign Compd. Biol. Syst."},{"key":"ref_13","first-page":"4029","article-title":"Application of nanoparticles for oral delivery of acid-labile lansoprazole in the treatment of gastric ulcer: In vitro and in vivo evaluations","volume":"10","author":"Alai","year":"2015","journal-title":"Int. J. Nanomed."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"122","DOI":"10.3109\/02652048.2010.535621","article-title":"Design and development of gliclazide-loaded chitosan for oral sustained drug delivery: In vitro\/in vivo evaluation","volume":"28","author":"Barakatm","year":"2011","journal-title":"J. Microencapsul."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1046\/j.1365-2036.2002.01138.x","article-title":"Lansoprazole vs. omeprazole for gastro-oesophageal reflux disease: A pH-metric comparison","volume":"16","author":"Frazzoni","year":"2002","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3109\/02652040903131301","article-title":"Microencapsulation techniques, factors influencing encapsulation efficiency","volume":"27","author":"Jyothi","year":"2010","journal-title":"J. Microencapsul."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1208\/s12248-013-9499-x","article-title":"International guidelines for bioequivalence of systemically available orally administered generic drug products: A survey of similarities and differences","volume":"15","author":"Davit","year":"2013","journal-title":"AAPS J."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1208\/s12248-014-9570-2","article-title":"Similarities and differences of international guidelines for bioequivalence: An update of the Brazilian requirements","volume":"16","author":"Rediguieri","year":"2014","journal-title":"AAPS J."},{"key":"ref_19","first-page":"271","article-title":"The study of the antiulcer of fructus schisandrae","volume":"31","author":"Yang","year":"2015","journal-title":"J. Harbin Commun."},{"key":"ref_20","first-page":"93","article-title":"Experimental study on the therapeutic effect of weiwei fang on gastric ulcer rats","volume":"41","author":"Zhuo","year":"2009","journal-title":"New TCM"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/0016-5085(88)90661-0","article-title":"Histology of alcoholic hemorrhagic \u201cgastritis\u201d: A prospective evaluation","volume":"94","author":"Laine","year":"1988","journal-title":"Gastroenterology"},{"key":"ref_22","unstructured":"(2006). Drug Class Review: Cyclo-Oxygenase (COX)-2 Inhibitors and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Final Report Update 3, Oregon Health & Science University."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.talanta.2011.11.063","article-title":"A fast, sensitive, and high throughput method for the determination of cefuroxime lysine in dog plasma by UPLC\u2013MS\/MS","volume":"89","author":"Zhao","year":"2012","journal-title":"Talanta"},{"key":"ref_24","unstructured":"Food and Drug Administration (2008). Guidance for Industry: Bioanalytical Method Validation."},{"key":"ref_25","unstructured":"ICH (1996). ICH Harmonization Tripartite Guideline. Guidelines for Good Clinical Practice. International Conference of Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Uses, ICH."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"4740","DOI":"10.1039\/C7AY01546A","article-title":"UPLC-MS\/MS method for determination of schisandrin in rat plasma and brain microdialysates: Application to a comparative pharmacokinetic and brain distribution study in normal and Alzheimer\u2019s disease rats","volume":"9","author":"Wei","year":"2017","journal-title":"Anal. Methods"},{"key":"ref_27","first-page":"280","article-title":"The effects of the Liujunzi decoction and its removal on the level of pepsin, SOD and MDA in spleen deficiency gastric ulcer model rats","volume":"26","author":"Bi","year":"2010","journal-title":"J. N. J. Univ. Chin. Med."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/11\/2\/49\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:27:54Z","timestamp":1760185674000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/11\/2\/49"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,22]]},"references-count":27,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,2]]}},"alternative-id":["pharmaceutics11020049"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics11020049","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,22]]}}}